Effects of multidrug resistance gene expression in acute erythroleukemia

Modern Pathology

Volumn 13, Issue 4, 2000, Pages 407-413

  Mazzella, Fermina M ^a,e   Kowal Vern, Areta ^b   Atef Shrit, M ^c   Rector, James T ^d   Cotelingam, James D ^d   Schumacher, Harold R ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c MIAMI VALLEY HOSPITAL   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

Acute erythroleukemia; Multidrug resistance gene (MDR 1); P glycoprotein

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOGENETICS; ERYTHROLEUKEMIA; FEMALE; HUMAN; HUMAN TISSUE; KARYOTYPE; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0034004682     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880070     Document Type: Article

References (26)

1. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta 1988;948:87-128.
2. Shustik C, Dalton W, Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 1995;16:l-78.
3. Sikic BI. Pharmacologie approaches to reversing multidrug resistance. Semin Hematol 1997;34:4(Suppl 5):40-7.
4. Kowal-Vern A, Cotelingam J, Schumacher HR. The prognostic significance of proerythroblasts in acute erythroleukemia. Am J Clin Pathol 1992;98:34-40.
5. Cuneo A, Van Orshoven A, Michaux JL, Boogaerts M, Louwagie A, Doyen C, et al. Morphologic, immunologie and cytogenetic studies in erythroleukemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types. Br J Haematol 1990; 75:346-54.
6. Mazzella FM, Kowal-Vern A, Shrit MA, \Vibowo AL, Rector JT, Cotelingam JD, et al. Acute erythroleukemia: evaluation of forty-eight cases with reference to classification, cell proliferation, cytogenetics and prognosis. Am J Clin Pathol 1998; 110:590-8.
7. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992;19:47-84.
8. Aiky R. Physicians' desk reference, 48th ed. Montvale, NJ: Medical Economics Data; 1994. pp. 673, 688, 825, 1539, 2072-73.
9. Willman C. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group leukemia research program. Semin Hematol 1997;34: 4(Suppl 5):25-33.
10. Hsu SM, Cossman J, Jaffe ES. A comparison of ABC, unlabelled antibody, and conjugated immunohistochemical methods with monoclonal and polyclonal antibodies: an examination of germinal center tonsils. Am J Clin Pathol 1983;80:429.
11. Kawai K, Serizawa A, Hamana T, Tsutsumi Y. Heat-induced antigen retrieval of proliferating cell nuclear antigen and p53 protein in formalin-fixed, paraffin-embedded sections. Pathol Int 1994;44:759-64.
12. Mazzella FM, Tolbert D, Kowal-Vern A, Shrit MA, Rector JT, Cotelingam JD, et al. P53 gene mutation in acute erythroleukemia: differences among subtypes M6a, M6b and M6c. Lab Hematol 1999;5:28-36.
13. Thottassery JV, Zambetti GP, Armori K, Schuetz EG, Schuetz JD. P53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997;94:11037-42.
14. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1992:255:459-62.
15. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997:57:4285-300.
16. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991:83:708-12.
17. Carulli G, Petrini M, Marini A, Vaglini F, Caracciolo F, Grassi B. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia. Haematologica 1990;75:516-21.
18. Pasman PC, Schouten HC. Multidrug resistance mediated by p-glycoprotein in hematological malignancies. Neth J Med 1993:42:218-31.
19. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987:316:1388-93.
20. Advani R, Saba HI, Tallman MS, Rowe JM, \Viernik PH, Ramek J, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999:93:787-95.
21. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78:586-92.
22. Sato H, Preisler H, Day R, Raza A, Larson R, Browman G, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 1990; 75:340-5.
23. Dalton WS. Mechanisms of drug resistance in hématologie malignancies. Semin Hematol 1997;34:4(Suppl 5):3-8.
24. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, et al. High dose cytosine arabinoside as the initial treatment of poor risk patients with acute non-lymphocytic leukemia: a Leukemia Intergroup Study. J Clin Oncol 1987;5:7582.
25. Preisler HD, Raza A. Chemotherapeutic strategies in the treatment of patients with acute non-lymphocytic leukemia in complete remission. Hem Rev 1987;2:13-43.
26. Suva M, Grillot D, Benito A, Richard C, Nunez G, FernandezLuna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bel-XL and Bcl-2. Blood 1996;88:1576-82.